



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

CMIE

In support of improving patient care, The Robert Larner College of Medicine at The University of Vermont is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Vermont designates this live activity for a maximum of **5 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program has been reviewed and is acceptable for up to **5 Nursing Contact Hours**.

The University of Vermont has been authorized by the American Academy of **Physician Assistants (AAPA)** to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for **5 AAPA Category 1 CME credits**. Physician Assistants should claim only the credit commensurate with the extent of their participation.

As a Jointly Accreditation Organization, The Robert Larner College of Medicine at the University of Vermont is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. The University of Vermont maintains responsibility for this course. **Social Workers** completing this course receive **5** continuing education credits.

This program has been approved through the Vermont Office of Professional Regulation for **5 hours** of continuing education credit for **Allied Mental Health Practitioners**.

This program is approved by the University of Vermont Doctor of Physical Therapy Program, a State of Vermont Office of Professional Regulation Approved Provider, for **5 CCUs** for **Physical Therapists** in the State of Vermont.

This program has been approved through the Vermont Office of Professional Regulation for **5** continuing education credit hours for **Psychological Examiners**.

This program is approved by The Commission on Dietetic Registration for **5** continuing education credit hours for **Registered Dietitians**.

This program was planned by and for the healthcare team, and learners will receive **5 Interprofessional Continuing Education (IPCE) credit** for learning and change.

Disclosure Information

Meeting Disclaimer: Regarding materials and information received during this educational event, the views, statements, and recommendations expressed during this activity represent those of the authors and speakers and do not necessarily represent the views of the University of Vermont.

Relevant Financial Relationships:* All those with control of content (speakers, planners, moderators, reviewers, staff) who have relevant financial relationships with “ineligible companies” are listed below. (An “ineligible company” is defined as one whose primary business is producing, marketing, selling, reselling or distributing healthcare products used by or on patients.) **All relevant financial relationships have been mitigated.**

- **Don Dizon, MD-** Astra Zeneca (consulting: DMC for two trials, DUO-O and DUO-E), GSK (consulting, DMC for RUBY), BMS (Institutional support for IST, ovarian), MIDI and Doximity (Stock options).
- **Eleonora Teplinsky, MD-** Sermo (medical advisory board member); AchieveCE (Honoraria); IntegrityCE (Honoraria); BonumCE (Honoraria); TotalHealthConferencing (Honoraria); GlaxoSmithKline (Consulting/Advisory Role), Eisai (Consulting/Advisory Role), FloHealth (Consulting/Advisor).

The following speakers have indicated that they will be discussing the unlabeled use of a commercial product:

- **Stephanie Goff, MD-** Discussing tumor infiltrating lymphocytes as part of a cell transfer strategy that includes chemotherapy, pembrolizumab, and aldesleukin
- **Devoot Majumdar, PhD-** mRNA cancer immunotherapies are not on the market or available outside of Phase I trials.
- **Hibba tul Rehman, MD-** FDA approval is pending for tumor infiltrating lymphocyte therapy but is expected in near future.

Support Received from Ineligible Companies:

We have not received any grant support for this activity from ineligible entities.

*Having a financial relationship with an ineligible company, **or discussing an unlabeled use of product**, may not prevent a speaker from making a presentation. However, the existence of the relationship must be made known to the planning committee prior to the conference, so that any relevant financial interest may be mitigated prior to the talk.

Learners are advised that accredited status does not imply endorsement by the provider of any commercial products displayed in conjunction with an activity.